Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 63.17% | 45.14% | -11.58% | 1.12% | 23.01% |
| Gross Profit | -63.17% | -45.14% | 11.58% | -1.12% | -23.01% |
| SG&A Expenses | 36.86% | 27.51% | 16.37% | 9.33% | 2.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.19% | 41.21% | -6.66% | 2.70% | 17.64% |
| Operating Income | -57.19% | -41.21% | 6.66% | -2.70% | -17.64% |
| Income Before Tax | 1.41% | -54.07% | -11.08% | 83.80% | 5.46% |
| Income Tax Expenses | -- | -- | -100.00% | -- | -- |
| Earnings from Continuing Operations | 1.41% | -54.12% | -11.07% | 83.80% | 5.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.41% | -54.12% | -11.07% | 83.80% | 5.46% |
| EBIT | -57.19% | -41.21% | 6.66% | -2.70% | -17.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 25.60% | -23.83% | 12.65% | 85.86% | 13.57% |
| Normalized Basic EPS | -16.16% | -69.60% | 18.25% | 86.35% | 9.52% |
| EPS Diluted | 25.60% | -23.83% | 12.65% | 85.86% | 13.57% |
| Normalized Diluted EPS | -16.16% | -69.60% | 18.25% | 86.35% | 9.52% |
| Average Basic Shares Outstanding | 40.43% | 30.34% | 35.88% | 18.72% | 32.93% |
| Average Diluted Shares Outstanding | 40.43% | 30.34% | 35.88% | 18.72% | 32.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |